Showing session: reset
Cyclin-dependent Kinase and PARP Inhibitor Clinical Trials
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease
Hope S Rugo
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
Fabrice Andre
Institut Gustave Roussy, Université Paris-Sud, Villejuif, France
- Free
- slides video
- audio + slides
- All slides included
Discussant
Filipa Lynce
Georgetown University, Washington, DC, United States
- Free
- audio + slides
- Some slides withheld
Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with RAS mutant solid tumors
Geoffrey I. Shapiro
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
Geoffrey I. Shapiro
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Timothy A. Yap
Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy
Anna F Farago
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
- Permission not
granted for presentation
Discussant
Caroline Dive
Cancer Research UK Manchester Inst., Manchester, United Kingdom